Skip to main content
BPH ENERGY LTD logo

BPH ENERGY LTD — Investor Relations & Filings

Ticker · BPH ISIN · AU000000BPH4 ASX Financial and insurance activities
Open in API
Filings indexed 1,483 across all filing types
Latest filing 2009-08-10 Regulatory Filings
Country AU Australia
Listing ASX BPH

About BPH ENERGY LTD

https://www.bphenergy.com.au/

BPH Energy Ltd is a diversified investment company focused on the commercialization of biomedical technologies and the exploration of energy resources. The company maintains a significant portfolio in the biotechnology sector, notably through its investment in Cortical Dynamics Ltd, which develops the Brain Anaesthesia Response Monitor (BARM) for objective measurement of anesthetic effect. In the energy sector, BPH Energy holds a substantial interest in Advent Energy Ltd, an unlisted oil and gas exploration company with assets including the PEP 11 permit in the offshore Sydney Basin. Additionally, the company has expanded its focus into sustainable energy through investments in Clean Hydrogen Technologies, which utilizes proprietary processes to produce turquoise hydrogen and solid carbon. BPH Energy aims to identify and develop high-growth opportunities within the healthcare and resource sectors to create long-term value.

Recent filings

Filing Released Lang Actions
US Patent Granted for HLS5 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement dated 11 August 2009 from BioPharmica Limited regarding the granting of a US patent for the HLS5 tumour suppressor gene. It discusses the patent issuance, the research background, and the company's patent portfolio and licensing intentions. There are no financial statements, regulatory certifications, or detailed financial data. The document is short (2103 characters) and serves as a news announcement about intellectual property rights rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Regulatory Filings. The best fitting category is a general regulatory announcement about company developments, which falls under Regulatory Filings (RNS).
2009-08-10 English
BPH Confirms 100% Ownership of New Anti Cancer Agents 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 August 2009 from BioPharmica Limited. It discusses a new agreement with the University of Western Australia regarding ownership of intellectual property related to anti-cancer agents. The announcement details the terms of the agreement, the appointment of a lead scientist, and the commercial potential of the research. There are no financial statements, quarterly or annual results, or regulatory certifications present. The document is relatively short (2862 characters) and serves as a corporate update on intellectual property and research developments rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a management or board change announcement, nor a voting result or capital update. The content is best classified as a general regulatory announcement about company developments, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2009-08-09 English
New Anti-Mitotic Drug Development for Pre-Clinical Testing 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 August 2009 from BioPharmica regarding the development of a new anti-mitotic drug for pre-clinical testing. It discusses scientific progress and potential commercial development but does not contain financial statements, regulatory certifications, voting results, or management changes. It is a corporate announcement about a product development milestone rather than a financial report, regulatory filing, or meeting material. Given the content and length (2551 characters), it is not a full report but an announcement of a development update. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2009-08-09 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and includes detailed consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statements. It is a quarterly report with actual financial data for the quarter ended 30 June 2009. The document is 7289 characters long, which is substantial and contains substantive financial data and analysis, not just an announcement or certification. The content aligns with a comprehensive interim or quarterly financial report rather than a brief earnings release or an announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2009
2009-07-12 English
BPH Audio Webcast Link 1 page ?Kb
Investor Presentation Classification · 80% confidence The document is an ASX announcement dated 1 July 2009 from BioPharmica Limited. It announces an audio webcast summarizing the current commercialisation status of its projects and provides a link to listen to the presentation. The document is short (1086 characters) and does not contain any financial data, detailed report content, or regulatory filings. It is essentially an announcement of a presentation event rather than the presentation or report itself. Therefore, it fits best as an Investor Presentation (IP) announcement. However, since it only announces the webcast and does not contain the presentation content itself, and given the short length, it is more appropriate to classify it as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). The document is not a certification or voting result, nor does it fit other categories. Given the nature of the announcement and the link to a webcast presentation, the best fit is Investor Presentation (IP) with moderate confidence, but considering the short length and announcement style, Regulatory Filings (RNS) is also plausible. Since the document is announcing a webcast presentation, the best classification is Investor Presentation (IP).
2009-06-30 English
BPH Current Commercialisation Status Presentation 19 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed company overview presentation from BioPharmica Limited dated July 2009. It provides broad information about the company's projects, technology, corporate structure, strategic position, intellectual property, and commercial potential. There are no financial statements, regulatory disclosures, voting results, or management changes. The content is focused on business strategy, technology descriptions, and market potential, typical of an investor presentation. The length (15,000 characters) and detailed content confirm it is not a brief announcement or a simple report publication notice. Therefore, the document fits best as an Investor Presentation (IP).
2009-06-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.